1800 103 7100
info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

Biogen Idec Given “Neutral” Rating at Piper Jaffray (BIIB) – Mideast Time

July 3, 2013Monoclonal Anti-IL-2Rα Receptor Antibodiesadmin

Biogen Idec Given “Neutral” Rating at Piper Jaffray (BIIB)
Mideast Time
... in particular unpublished estimates) now fully reflect Tecfidera's strong launch, in our view, and upside in BIIB shares will likely require pipeline success, which is not expected until 2014 data readouts from anti-LINGO Phase II (optic neuritis ...

and more »

Post navigation

← Daclizumab (Multiple Sclerosis) – Forecast and Market Analysis to 2022: New … – SBWire (press release) Blood Banking in Europe: Market Segment Forecasts and Supplier Shares – The Herald | HeraldOnline.com →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Powered by WordPress , Theme i-excel by TemplatesNext.
MENU
    • About
    • Free Downloads
    • Videos